2025 Year in Review — And the Road Ahead
As we close out 2025, I want to take a moment to reflect on the incredible progress we have made together and share a preview of the transformational year ahead.
This has been a pivotal year for Vector BioSource. We strengthened our foundation, expanded our capabilities, and continued to deliver trusted biospecimen access to research partners across the globe. Every milestone we hit this year was achieved because of a team that shows up with passion, purpose, and unwavering focus and I cannot thank you enough.
2025 Highlights
We continued to grow our footprint and revenue across the United States.
We advanced our preparedness for operating FDA-licensed blood collection facilities, giving Vector a critical role in the future of research-grade biospecimen supply.
We deepened our sourcing network and expanded our reach into new regions around the world.
We improved operational efficiency, strengthened key partnerships, and positioned the company for scalable expansion.
Each of these accomplishments represents strategic groundwork and foundation for the next chapter.
What’s Coming in 2026
2026 will be the year Vector BioSource truly steps into its next evolution:
Major expansion across the United States
Global sourcing initiatives unlocking rare and disease-state biospecimens
Full integration of FDA-licensed collection facilities
Launch and rollout of Vector Hub, our real-time mobile and AI platform connecting donors, research organizations, and global discovery like never before
New partnerships that enhance our logistics and cold-chain capabilities to reach any researcher, anywhere.
Most importantly, this growth means we can support faster discoveries, better diagnostics, and life-changing science — on a scale we’ve never achieved before.
We are welcoming new talent into Vector in 2026 with leaders and experts who will support our rapid expansion and strengthen every level of our organization. At the same time, we continue to honor the incredible team members who have been with us from the beginning. Together, we are building a culture that grows with opportunity while staying true to our mission and values.
A sincere thank-you goes to FOXO Technologies for the belief and support that helped turn our vision into momentum. Their partnership enables us to move faster, reach further, and execute a bold strategy that positions Vector success.
I’ve said it before — Vector is just getting started.
2025 was our launchpad.
2026 is our lift-off.
To our team, our partners, and the scientific community we proudly serve:
Thank you for trusting us, believing in us, and helping us build the future of biospecimen access.
Let’s make 2026 the year we change the industry together.
